PDF(Pubmed)
Abstract：
UNASSIGNED: For patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we collected the prospective data reported since 2010 to analyze the emerging chemotherapy-based treatments in ATC comprehensively.
UNASSIGNED: For this updated analysis, we searched PubMed (MEDLINE), Web of Science, Embase, and Cochrane CENTRAL databases from 1 January 2010 to 7 February 2024 for prospective clinical studies that contained chemotherapy-based treatments. This analysis was done to pool overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), disease control rates (DCRs), and grade 3 or worse treatment-related adverse events (TRAEs).
UNASSIGNED: Six prospective clinical trials with 232 patients were included. Chemotherapy was commonly combined with targeted therapy or radiotherapy. The pooled median OS was 6.0 months (95% CI 4.1-9.7), and the median PFS was 3.2 months (95% CI 1.9-6.0) in patients with ATC who received chemotherapy-based strategies. The integrated ORR and DCR were 21% (95% CI 15%-27%) and 64% (95% CI 55%-72%), respectively. Regarding the grade 3 or worse TRAE, the pooled incidence was 68% (95% CI 47%-86%).
UNASSIGNED: Although the emerging chemotherapy-based treatments showed antitumor activity in patients with ATC, these strategies failed to prolong the survival time substantially. More practical, safe, and novel therapeutic regimens for patients with ATC warrant further investigations.
UNASSIGNED: For this updated analysis, we searched PubMed (MEDLINE), Web of Science, Embase, and Cochrane CENTRAL databases from 1 January 2010 to 7 February 2024 for prospective clinical studies that contained chemotherapy-based treatments. This analysis was done to pool overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), disease control rates (DCRs), and grade 3 or worse treatment-related adverse events (TRAEs).
UNASSIGNED: Six prospective clinical trials with 232 patients were included. Chemotherapy was commonly combined with targeted therapy or radiotherapy. The pooled median OS was 6.0 months (95% CI 4.1-9.7), and the median PFS was 3.2 months (95% CI 1.9-6.0) in patients with ATC who received chemotherapy-based strategies. The integrated ORR and DCR were 21% (95% CI 15%-27%) and 64% (95% CI 55%-72%), respectively. Regarding the grade 3 or worse TRAE, the pooled incidence was 68% (95% CI 47%-86%).
UNASSIGNED: Although the emerging chemotherapy-based treatments showed antitumor activity in patients with ATC, these strategies failed to prolong the survival time substantially. More practical, safe, and novel therapeutic regimens for patients with ATC warrant further investigations.
摘要：
■对于没有突变驱动基因的未分化甲状腺癌（ATC）患者，化疗被认为是一线治疗选择.然而,化疗治疗ATC的益处有限.在这个分析中,我们收集了自2010年以来报告的前瞻性数据,以全面分析ATC中新兴的基于化疗的治疗方法.
■对于此更新的分析，我们搜索了PubMed(MEDLINE)，WebofScience,Embase,2010年1月1日至2024年2月7日的CochraneCENTRAL数据库,用于包含基于化疗的治疗的前瞻性临床研究.这项分析是为了汇集总生存率(OS)，无进展生存期（PFS），客观反应率(ORR)，疾病控制率（DCRs），和3级或更严重的治疗相关不良事件（TRAEs）。
■纳入了对232名患者的6项前瞻性临床试验。化疗常联合靶向治疗或放疗。合并的中位OS为6.0个月(95%CI4.1-9.7)，接受化疗策略的ATC患者的中位PFS为3.2个月(95%CI1.9-6.0).综合ORR和DCR分别为21%(95%CI15%-27%)和64%(95%CI55%-72%)，分别。关于三年级或更糟糕的TRAE，合并发生率为68%(95%CI47%-86%).
■尽管新兴的基于化疗的治疗在ATC患者中显示出抗肿瘤活性，这些策略未能显著延长生存时间.更实用,安全,ATC患者的新治疗方案需要进一步研究。
■对于此更新的分析，我们搜索了PubMed(MEDLINE)，WebofScience,Embase,2010年1月1日至2024年2月7日的CochraneCENTRAL数据库,用于包含基于化疗的治疗的前瞻性临床研究.这项分析是为了汇集总生存率(OS)，无进展生存期（PFS），客观反应率(ORR)，疾病控制率（DCRs），和3级或更严重的治疗相关不良事件（TRAEs）。
■纳入了对232名患者的6项前瞻性临床试验。化疗常联合靶向治疗或放疗。合并的中位OS为6.0个月(95%CI4.1-9.7)，接受化疗策略的ATC患者的中位PFS为3.2个月(95%CI1.9-6.0).综合ORR和DCR分别为21%(95%CI15%-27%)和64%(95%CI55%-72%)，分别。关于三年级或更糟糕的TRAE，合并发生率为68%(95%CI47%-86%).
■尽管新兴的基于化疗的治疗在ATC患者中显示出抗肿瘤活性，这些策略未能显著延长生存时间.更实用,安全,ATC患者的新治疗方案需要进一步研究。
